Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Type 1 or type 2 diabetes
Treatment with insulin and/or oral anti-diabetic drugs
Asthma for at least 6 months
Positive airway reversibility/bronchoprovocation test or documented positive test in the last 3 years
HbA1C less than or equal to 11.0 %
Body Mass Index (BMI) less than or equal to 40.0 kg/m2
You may not be if
Current smoking or smoking within the last 6 months
Other current acute or chronic pulmonary disease excluding asthma
Recurrent severe hypoglycaemia
Proliferative retinopathy or maculopathy
Clareo Health | Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma
